Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation

Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation

Post Views: 181 Insilico Medicine, a global clinical-stage biotechnology company specializing in the applications of end-to-end artificial intelligence (AI) for drug discovery and development, today announced that the company has nominated preclinical candidates (PCC) for ISM012-077 and ISM012-042 for the treatment of anemia of chronic kidney disease (CKD) and inflammatory bowel disease (IBD), respectively.ISM012-077 and…